Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Abstract Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with advanced, unresect...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine S. Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David Propper
Aineistotyyppi: Artigo
Kieli:englanti
Julkaistu: 2020
Linkit:https://doi.org/10.1038/s41467-020-18636-w
https://www.nature.com/articles/s41467-020-18636-w.pdf
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

https://doi.org/10.1038/s41467-020-18636-w
https://www.nature.com/articles/s41467-020-18636-w.pdf

Samankaltaisia teoksia